In a filing, Protagonist Therapeutics Inc revealed its President and CEO PATEL DINESH V PH D unloaded Company’s shares for reported $0.2 million on Feb 19 ’25. In the deal valued at $38.18 per share,5,359 shares were sold. As a result of this transaction, PATEL DINESH V PH D now holds 540,260 shares worth roughly $19.45 million.
Then, MOLINA ARTURO MD sold 26,000 shares, generating $1,162,280 in total proceeds. Upon selling the shares at $44.70, the Chief Medical Officer now owns 46,444 shares.
Before that, MOLINA ARTURO MD sold 5,529 shares. Protagonist Therapeutics Inc shares valued at $252,122 were divested by the Chief Medical Officer at a price of $45.60 per share. As a result of the transaction, MOLINA ARTURO MD now holds 46,444 shares, worth roughly $1.67 million.
Goldman initiated its Protagonist Therapeutics Inc [PTGX] rating to a Neutral in a research note published on December 06, 2024; the price target was $47. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Wedbush began covering PTGX with “an Outperform” recommendation on November 05, 2024. TD Cowen started covering the stock on September 24, 2024. It rated PTGX as “a Buy”.
Price Performance Review of PTGX
On Friday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock fall -7.10% to $36.00. Over the last five days, the stock has lost -6.90%. Protagonist Therapeutics Inc shares have fallen nearly -6.74% since the year began. Nevertheless, the stocks have risen 34.43% over the past one year. While a 52-week high of $48.89 was reached on 01/03/25, a 52-week low of $24.22 was recorded on 01/16/25. SMA at 50 days reached $38.55, while 200 days put it at $39.28.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 34.93, which if violated will result in even more drops to 33.87. On the upside, there is a resistance level at 37.99. A further resistance level may holdings at 39.99. The Relative Strength Index (RSI) on the 14-day chart is 40.15, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.53%. Stochastics %K at 45.31% indicates the stock is a holding.
The most recent change occurred on September 09, 2024 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
